NRAS and melanoma: Here we show that co-administration of 17-AAG inhibits the paradoxical activation of MAP kinase signaling observed in PLX-treated BRAFWT, NRAS-mutant human melanoma cells, providing experimental support for the notion that co-administration may block the expansion of nascent, RAS-mutant clones in PLX-treated melanomas.